Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center and post germinal center B-cells.
Diffuse Large B-Cell Lymphoma Epidemiology Insights
DLBCL, NOS cases in the United States in 2017 – 24,933
The age-group with the highest incidence of DLBCL among 7MM in 2017 was 65–74 years
Males have higher incident cases of DLBCL as compared to females
Diffuse Large B-Cell Lymphoma Epidemiology Segmentation in 7MM from 2017 to 2030
Scope of the Report
Request for sample pagesTable of contents
1. Key Insights
2. Executive Summary of Diffuse Large B-cell Lymphoma
3. Diffuse Large B-cell Lymphoma: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Diffuse Large B-cell Lymphoma Treatment and Management
6.2. Diffuse Large B-cell Lymphoma Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/